title: Survival following Ommaya reservoir placement for neoplastic meningitis.
abstract: The objective of this study was to evaluate the outcomes of patients with neoplastic meningitis (NM) following Ommaya reservoir placement in order to determine whether any patient factors are associated with longer survival. NM is a devastating late manifestation of cancer, and given its dismal prognosis, identifying appropriate patients for Ommaya reservoir placement is difficult. The authors performed a retrospective review of 80 patients who underwent Ommaya reservoir placement at three medical centers from September 2001 through September 2012. The primary outcome was death. Differences in survival were assessed with Kaplan-Meier survival analyses. The Cox proportional hazards and logistic regression modeling were performed to identify factors associated with survival. The primary diagnoses were solid organ, hematologic, and primary central nervous system tumors in 53.8%, 41.3%, and 5%, respectively. The median overall survival was 72.5 days (95% confidence interval 36-122) with 30% expiring within 30 days and only 13.8% surviving more than 1 year. There were no differences in median overall survival between sites (p=0.37) despite differences in time from diagnosis of NM to Ommaya reservoir placement (p<0.001). Diagnosis of hematologic malignancy was inversely associated with death within 90 days (p=0.04; odds ratio 0.34), older age was associated with death within 90 days (p=0.05; odds ratio 1.5, per 10 year increase in age). The prognosis of NM remains poor despite the available treatment with intraventricular chemotherapy. There exists significant variability in treatment algorithms among medical centers and consideration of this variability is crucial when interpreting existing series of Ommaya reservoir use in the treatment of patients with NM.
authors.affiliation: Department of Neurosurgery, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA.
authors.forename: Marie
authors.initials: M
authors.lastname: Roguski
authors.affiliation: Neuroscience Institute, Maine Medical Center, Portland, ME, USA.
authors.forename: Anand
authors.initials: A
authors.lastname: Rughani
authors.affiliation: Division of Neurosurgery, University of Vermont, Medical Center, Burlington, VT, USA.
authors.forename: Chih-Ta
authors.initials: CT
authors.lastname: Lin
authors.affiliation: Neuroscience Institute, Maine Medical Center, Portland, ME, USA.
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Cushing
authors.affiliation: Neuroscience Institute, Maine Medical Center, Portland, ME, USA.
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Florman
authors.affiliation: Department of Neurosurgery, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA. Electronic address: jwu3@tuftsmedicalcenter.org.
authors.forename: Julian K
authors.initials: JK
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D057967:Infusions, Intraventricular; D053208:Kaplan-Meier Estimate; D008297:Male; D055756:Meningeal Carcinomatosis / Q000401:mortality / Q000601:surgery*; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D019736:Prostheses and Implants; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents
keywords: Carcinomatous meningitis; Intraventricular chemotherapy; Neoplastic meningitis; Ommaya reservoir